CureVac reaches settlement with BioNTech, Pfizer over COVID-19 vaccine patents
August 9, 2025
Source: drugdu
82
August 8, German biotechnology company CureVac announced on August 8 local time that CureVac and GlaxoSmithKline have partnered with BioNTech and Pfizer toAn agreement was reached to resolve and dismiss all outstanding patent lawsuits filed by several companies in the United States regarding mRNA-based COVID-19 vaccines, and to establish a framework for resolving ongoing patent disputes outside the United States. Under the terms of the agreement, CureVac and GlaxoSmithKline will receive a total of $740 million in payments and single-digit royalties on future sales of the COVID-19 vaccine in the United States. In addition, CureVac will receive $50 million in U.S. product royalties from GlaxoSmithKline. In addition, as part of the settlement, CureVac will grant BioNTech and Pfizer a non-exclusive license to produce, use, import and sell mRNA-based COVID-19 and/or influenza vaccines in the United States.This non-exclusive license will be expanded to a global license upon completion of BioNTech's acquisition of CureVac.
https://finance.eastmoney.com/a/202508083479855520.html
Copyright©2025 Ddu. All rights reserved.
Read more on
- Zhengda Tianqing targets 9.2 billion yuan drug September 18, 2025
- Announcement on the Holding Subsidiary Obtaining Medical Device Registration Certificate September 18, 2025
- Plans to invest RMB 42.74 million in Wuhan Huajiyuan to advance clinical trials of the therapeutic antihypertensive vaccine (HJY-ATRQβ-001) project September 18, 2025
- Eli Lilly wins again! Oral weight loss drug outperforms oral sirolimus in head-to-head tria September 18, 2025
- Hengrui’s breakthrough hepatitis B therapy arrives September 17, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
